**WHY CIRCULOGENE**

CIRCULOGENE’s molecular diagnostics process is based on the discovery that tumor cells multiply, they also die, releasing their DNA into the bloodstream. CIRCULOGENE’s comprehensive tumor DNA sequencing is the only testing available that combines minimal volumes of blood with the most advanced next-generation sequencing (NGS) to monitor tumor-mutant DNA within well-characterized, well-documented, cancer-associated genes.

**CIRCULOGENE’S SOLUTION**

At CIRCULOGENE our approach characterizes genomic changes to give patients and their treatment teams the most comprehensive information possible in order to make programmatic treatment decisions faster.

CIRCULOGENE’S LISA Enrichment Technology

CIRCULOGENE’S Proprietary Enrichment Technology, LISA (Liquid In Situ Amplification), is the ONLY technology that bypasses the purification step, which is important because genetic material will not be lost.

**ACCESS**

Minimal-volume input with maximal yield. One lavender tube (4mL) for full range of DNA, RNA, and MSI immunotherapy testing.

**ENRICH**

Proprietary, direct-on-specimen enrichment technology locates and captures cell-free DNA.

**DETECT**

Capable of testing more than 50 genes for approximately 5,000 possible mutations.

**THE CHALLENGES WITH TISSUE**

For many years, tissue samples have been standard procedure for tumor testing and even for next generation sequencing. However, tissue sampling comes with a series of challenges including time, efficacy, and patient comfort.

**ACQUIRED RESISTANCE IS FREQUENTLY CHARACTERIZED BY PROFOUND TUMOR HETEROGENEITY**

"Acquired resistance is frequently characterized by profound tumor heterogeneity, and the emergence of multiple resistance alterations in the individual patient may represent the “rule” rather than the “exception.” These findings have profound therapeutic implications and highlight potential advantages of cfDNA over tissue biopsy in the setting of acquired resistance." - Nature Medicine vol25, sept 2019

"Although liquid biopsies are being studied in a number of cancers, it is particularly important for patients with gastric cancer because it can be difficult to get enough tissue from the tumor to get all of the genetic testing physicians need for these patients with a tissue biopsy. When using liquid biopsies physicians will be provided with so much data that they may have otherwise been able to obtain with a tissue biopsy. As liquid biopsies became more widespread, the potential to change the landscape of treatments that physicians can offer patients in the setting of acquired resistance.

At CIRCULOGENE our approach characterizes genomic changes to give patients and their treatment teams the most comprehensive information possible in order to make programmatic treatment decisions faster.

CIRCULOGENE Proprietary Enrichment Technology, LISA (Liquid In Situ Amplification), is the ONLY technology that bypasses the purification step, which is important because genetic material will not be lost.

“Although liquid biopsies are being studied in a number of cancers, it is particularly important for patients with gastric cancer because it can be difficult to get enough tissue from the tumor to get all of the genetic testing physicians need for these patients with a tissue biopsy. When using liquid biopsies physicians will be provided with so much data that they may have otherwise been able to obtain with a tissue biopsy. As liquid biopsies became more widespread, the potential to change the landscape of treatments that physicians can offer patients in the setting of acquired resistance.

At CIRCULOGENE our approach characterizes genomic changes to give patients and their treatment teams the most comprehensive information possible in order to make programmatic treatment decisions faster.

CIRCULOGENE Proprietary Enrichment Technology, LISA (Liquid In Situ Amplification), is the ONLY technology that bypasses the purification step, which is important because genetic material will not be lost.

**TISSUE ONLY APPROACH:**

Step 1: Tissue Biopsy

Step 2: Diagnosis

Step 3: Multi-Disciplinary Discussion

Step 4: Block Procurement, Biomarkers Ordered (if sufficient tissue)

Step 5: Tissue results back

Step 6: Treatment

> > >

> > >

**ACCESS**

Minimal-volume input with maximal yield. One lavender tube (4mL) for full range of DNA, RNA, and MSI immunotherapy testing.

**ENRICH**

Proprietary, direct-on-specimen enrichment technology locates and captures cell-free DNA.

**DETECT**

Capable of testing more than 50 genes for approximately 5,000 possible mutations.
GASTROINTESTINAL (GI) CANCERS ARE ONE OF THE GREATEST PUBLIC HEALTH ISSUES IN THE US and worldwide—leading to almost 4.5 million global deaths each year. According to the American Cancer Society (ACS) reported statistics, taken as a whole, gastrointestinal (GI) cancers have the highest incidence and are the second leading cause of cancer death in the United States.

“Patients with actionable alterations had a significantly longer median overall survival when treated with an appropriately matched therapy than patients with actionable alterations that did not receive matched therapy” - Lancet Oncol 2020

THE CIRCULOGENE DIFFERENCE: PROGRAMMATIC APPROACH

“The promise of precision oncology requires the application of biomarker testing to direct appropriate clinical care.” Lancet Oncol 2020

CIRCULOGENE gives all Four Pillars of Gastrointestinal Care the ability to construct optimal treatment plans for patients in a multi-disciplinary, time-effective approach.

TIME MATTERS

Every 2.3 minutes there is a newly diagnosed cancer patient, which means time is crucial and time to treatment matters! Patients getting more time with their loved ones matters!

“Are we performing precision medicine testing early enough in a patient’s course to begin therapy in an efficient manner and not impact on progression free survival? Of those tested it may have occurred too late in the course of these to improve outcomes. We are moving to a more systematic evaluation of these patients to capture and respond to these issues.” - GI ASCO 2020, Journal of Clinical Oncology 2020

CIRCULOGENE’s Comprehensive GI Panel is the easiest, most patient friendly decision that can be made at the time of biopsy.

COMPLETE BIOMARKER TESTING SOLUTION FOR YOUR PATIENT, BECAUSE IT MATTERS.

“Adherence to guideline recommended biomarker testing would potentially reduce exposure to expensive and ineffective therapies, resulting in improved patient outcomes.” - JCO Precision Oncology 2019

CIRCULOGENE's Comprehensive GI Panel includes all of the current NCCN targetable markers as well as all actionable markers and co-mutations so that you can make critical decisions in your patient’s treatment plan.

CIRCULOGENE SOLUTION

REQUIRES ONLY 4 ML OF BLOOD (ONE PURPLE TOP EDTA TUBE)

Step 1: Tissue Biopsy & CIRCULOGENE Blood Draw

Step 2: Diagnosis

Step 3: CIRCULOGENE Results

Step 4: Multi-Disciplinary Discussion

Step 5: Treatment Plan in 9 DAYS

TOTAL BIOMARKER TESTING SOLUTION FOR YOUR PATIENT, BECAUSE IT MATTERS.
“We believe that molecular testing of a patient’s tumors is key to successful cancer treatment.”

-GI Cancer Alliance

THE CHALLENGES WITH TISSUE

For many years, tissue samples have been standard procedure for tumor testing and even for next generation sequencing. However, tissue sampling comes with a series of challenges including time, efficiency, and patient comfort.

WHY CIRCULOGENE

CIRCULOGENE’s molecular diagnostics pipeline is based on the discovery that as tumor cells multiply, they also die, releasing their DNA into the bloodstream. CIRCULOGENE’s comprehensive tumor DNA sequencing is the only testing available that combines minimal volumes of blood with the most advanced next-generation sequencing (NGS) to monitor tumor-mutant DNA within well-characterized, well-documented, cancer-associated genes.

CIRCULOGENE’S SOLUTION

At CIRCULOGENE our approach characterizes genomic changes to give patients and their treatment teams the most comprehensive information possible in order to make programmatic treatment decisions faster.

CIRCULOGENE’S LISA Enrichment Technology

CIRCULOGENE’S Proprietary Enrichment Technology, LISA (Liquid In Situ Amplification), is the ONLY technology that bypasses the purification step, which is important because genetic material will not be lost.

ACCESS

Minimal-volume input with maximal yield. One lavender tube (4mL) for full range of DNA, RNA, and MSI immunotherapy testing.

ENRICH

Proprietary, direct-on-specimen enrichment technology locates and captures cell-free DNA

DETECT

Capable of testing more than 50 genes for approximately 5,000 possible mutations

For many years, tissue samples have been standard procedure for tumor testing and even for next generation sequencing. However, tissue sampling comes with a series of challenges including time, efficiency, and patient comfort.

“Acquired resistance is frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in the individual patient may represent the “rule” rather than the “exception.” These findings have profound therapeutic implications and highlight potential advantages of cfDNA over tissue biopsy in the setting of acquired resistance. -Nature Medicine vol25, sept 2019

At CIRCULOGENE our approach characterizes genomic changes to give patients and their treatment teams the most comprehensive information possible in order to make programmatic treatment decisions faster.

CIRCULOGENE PROPRIETARY ENRICHMENT TECHNOLOGY

CIRCULOGENE’s Liquid In Situ Amplification (LISA) Enrichment

87% success rate

Near-full cfDNA recovery

GETTING GASTROINTESTINAL CANCER PATIENTS ON THE RIGHT TREATMENT, FASTER; BECAUSE TIME MATTERS.

For many years, tissue samples have been standard procedure for tumor testing and even for next generation sequencing. However, tissue sampling comes with a series of challenges including time, efficiency, and patient comfort.

As CIRCULOGENE our approach characterizes genomic changes to give patients and their treatment teams the most comprehensive information possible in order to make programmatic treatment decisions faster.

CIRCULOGENE’s Liquid In Situ Amplification (LISA) Enrichment

87% success rate

Near-full cfDNA recovery

CIRCULOGENE PROPRIETARY ENRICHMENT TECHNOLOGY

CIRCULOGENE’s Liquid In Situ Amplification (LISA) Enrichment, is the ONLY technology that bypasses the purification step, which is important because genetic material will not be lost.

Although liquid biopsies are being tested in a number of cancers, it is particularly important for patients with gastric cancer because it can be difficult to get enough tissue from the tumor to get all of the genetic testing physicians need for these patients with a tissue biopsy. When using liquid biopsies physicians will be provided with so much data on the tumor that they may have otherwise not been able to analyze with a tissue biopsy. As liquid biopsies become more widely used, we are able to understand that physicians can offer patients in the future.

“Acquired resistance is frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in the individual patient may represent the “rule” rather than the “exception.” These findings have profound therapeutic implications and highlight potential advantages of cfDNA over tissue biopsy in the setting of acquired resistance. -Nature Medicine vol25, sept 2019

At CIRCULOGENE our approach characterizes genomic changes to give patients and their treatment teams the most comprehensive information possible in order to make programmatic treatment decisions faster.

CIRCULOGENE PROPRIETARY ENRICHMENT TECHNOLOGY

CIRCULOGENE’s Liquid In Situ Amplification (LISA) Enrichment

87% success rate

Near-full cfDNA recovery

CIRCULOGENE PROPRIETARY ENRICHMENT TECHNOLOGY

CIRCULOGENE’s Liquid In Situ Amplification (LISA) Enrichment, is the ONLY technology that bypasses the purification step, which is important because genetic material will not be lost.

Acquired resistance is frequently characterized by profound tumor heterogeneity, and the emergence of multiple resistance alterations in the individual patient may represent the “rule” rather than the “exception.” These findings have profound therapeutic implications and highlight potential advantages of cfDNA over tissue biopsy in the setting of acquired resistance. -Nature Medicine vol25, sept 2019

At CIRCULOGENE our approach characterizes genomic changes to give patients and their treatment teams the most comprehensive information possible in order to make programmatic treatment decisions faster.

CIRCULOGENE’S LISA Enrichment Technology

CIRCULOGENE’s Liquid In Situ Amplification (LISA) Enrichment

87% success rate

Near-full cfDNA recovery

CIRCULOGENE PROPRIETARY ENRICHMENT TECHNOLOGY

CIRCULOGENE’s Liquid In Situ Amplification (LISA) Enrichment, is the ONLY technology that bypasses the purification step, which is important because genetic material will not be lost.
GASTROINTESTINAL (GI) CANCERS ARE ONE OF THE GREATEST PUBLIC HEALTH ISSUES IN THE US and worldwide—leading to almost 4.5 million global deaths each year. According to the American Cancer Society (ACS) reported statistics, taken as a whole, gastrointestinal (GI) cancers have the highest incidence and are the second leading cause of cancer death in the United States.

"Patients with actionable alterations had a significantly longer median overall survival when treated with an appropriately matched therapy than patients with actionable alterations that did not receive matched therapy" - Lancet Oncol 2020

"Are we performing precision medicine testing early enough in a patient’s course to begin therapy in an efficient manner and make an impact on progression free survival? Of those tested, it may have occurred too late in the course of the illness to improve outcomes. We are moving to a more systematic evaluation of these patients to capture and respond to these issues." - GI ASCO 2020, Journal of Clinical Oncology 2020

THE CIRCULOGENE DIFFERENCE: PROGRAMMATIC APPROACH

"The promise of precision oncology requires the application of biomarker testing to direct appropriate clinical care." Lancet Oncol 2020

CIRCULOGENE gives all Four Pillars of Gastrointestinal Care the ability to construct optimal treatment plans for patients in a multi-disciplinary, time-effective approach.

A. Incidence and Mortality

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Incidence</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectal Cancer</td>
<td>140,000</td>
<td>37%</td>
</tr>
<tr>
<td>Pancreas Cancer</td>
<td>120,000</td>
<td>83%</td>
</tr>
<tr>
<td>Liver Cancer</td>
<td>100,000</td>
<td>69%</td>
</tr>
<tr>
<td>Esophagus Cancer</td>
<td>80,000</td>
<td>92%</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>60,000</td>
<td>71%</td>
</tr>
<tr>
<td>Stomach Cancer</td>
<td>40,000</td>
<td>44%</td>
</tr>
<tr>
<td>Other Cancer</td>
<td>20,000</td>
<td>22%</td>
</tr>
</tbody>
</table>

CIRCULOGENE's Comprehensive GI Panel includes all of the current NCCN targetable markers as well as all actionable markers and co-mutations so that you can make critical decisions in your patient's treatment plan.

TIME MATTERS

Every 2.3 minutes there is a newly diagnosed cancer patient, which means time is crucial and time to treatment matters!

Patients getting more time with their loved ones matters!

"Adherence to guideline recommended biomarker testing would potentially reduce exposure to expensive and ineffective therapies, resulting in improved patient outcomes." - JCO Precision Oncology 2019

"Starting the correct treatment as quickly as possible upon diagnosis improves survival!" - Gi ASCO 2020, Journal of Clinical Oncology 2020

CIRCULOGENE'S Comprehensive GI Panel is the easiest, most patient friendly decision that can be made at the time of biopsy.

COMPLETE BIOMARKER TESTING SOLUTION FOR YOUR PATIENT, BECAUSE IT MATTERS.

"Grey areas and holes in our knowledge base lead to unnecessary treatments with potential adverse side effects. We have the tools and the technical infrastructure to address this need for all patients." - JCO Precision Oncology 2019

CIRCULOGENE'S Comprehensive GI Panel includes all of the current NCCN targetable markers as well as all actionable markers and co-mutations so that you can make critical decisions in your patient's treatment plan.
"We believe that molecular testing of a patient’s tumors is key to successful cancer treatment.”
- GI Cancer Alliance

---

**THE CHALLENGES WITH TISSUE**

For many years, tissue samples have been standard procedure for tumor testing and even for next generation sequencing. However, tissue sampling comes with a series of challenges including time, efficiency, and patient comfort.

**WHY CIRCULOGENE**

CIRCULOGENE's molecular diagnostics process is based on the discovery that as tumor cells multiply, they also die, releasing their DNA into the bloodstream. CIRCULOGENE's comprehensive tumor DNA sequencing is the only testing available that combines minimal volumes of blood with the most advanced next-generation sequencing (NGS) to monitor somatic-mutant DNA within well-characterized, well-documented, cancer-associated genes.

**CIRCULOGENE’s Solution**

At CIRCULOGENE our approach characterizes genomic changes to give patients and their treatment teams the most comprehensive information possible in order to make programmatic treatment decisions faster.

**CIRCULOGENE’S LISA Enrichment Technology**

CIRCULOGENE Liquid In Situ Amplification (LISA) Enrichment

- 97% success rate
- Near-full eDNA recovery

**ACCESS**

Minimal-volume input with maximal yield. One lavender tube (4mL) for full range of DNA, RNA, and MSI immunotherapy testing.

**ENRICH**

Proprietary, direct-on-specimen enrichment technology locates and captures cell-free DNA

**DETECT**

Capable of testing more than 50 genes for approximately 5,000 possible mutations

---

**THE CHALLENGES WITH TISSUE**

"Although liquid biopsies are being tested in a number of centers, it is particularly important for patients with gastric cancer because it can be difficult to get enough tissue from the tumor to get all of the genetic testing physicians need for these patients with a tissue biopsy. When using liquid biopsies, physicians will be provided with the evidence to get this done, they may have otherwise not been able to obtain with a tissue biopsy. As liquid biopsies became more widely used, it is the potential to change the landscape of treatments that physicians can offer patients in the coming years."

Joseph Fox, MD, Chair of Surgical Oncology, University of Kentucky ASCO 2019

"Acquired resistance is frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in the individual patient may represent the “rule” rather than the “exception.” These findings have profound therapeutic implications and highlight potential advantages of eDNA over tissue biopsy in the testing of acquired resistance."

-Nature Medicine vol25, sept 2019

---

"Although liquid biopsies are being tested in a number of centers, it is particularly important for patients with gastric cancer because it can be difficult to get enough tissue from the tumor to get all of the genetic testing physicians need for these patients with a tissue biopsy. When using liquid biopsies, physicians will be provided with the evidence to get this done, they may have otherwise not been able to obtain with a tissue biopsy. As liquid biopsies became more widely used, it is the potential to change the landscape of treatments that physicians can offer patients in the coming years."

Joseph Fox, MD, Chair of Surgical Oncology, University of Kentucky ASCO 2019

"Acquired resistance is frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in the individual patient may represent the “rule” rather than the “exception.” These findings have profound therapeutic implications and highlight potential advantages of eDNA over tissue biopsy in the testing of acquired resistance."

-Nature Medicine vol25, sept 2019

---

*Tumor biopsy

Although liquid biopsies are being tested in a number of centers, it is particularly important for patients with gastric cancer because it can be difficult to get enough tissue from the tumor to get all of the genetic testing physicians need for these patients with a tissue biopsy. When using liquid biopsies, physicians will be provided with the evidence to get this done, they may have otherwise not been able to obtain with a tissue biopsy. As liquid biopsies became more widely used, it is the potential to change the landscape of treatments that physicians can offer patients in the coming years.

Joseph Fox, MD, Chair of Surgical Oncology, University of Kentucky ASCO 2019

"Acquired resistance is frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in the individual patient may represent the “rule” rather than the “exception.” These findings have profound therapeutic implications and highlight potential advantages of eDNA over tissue biopsy in the testing of acquired resistance."

-Nature Medicine vol25, sept 2019

---

"We believe that molecular testing of a patient’s tumors is key to successful cancer treatment.”
- GI Cancer Alliance

---

www.circulogene.com
855-380-1555
info@circulogene.com

---

"Although liquid biopsies are being tested in a number of centers, it is particularly important for patients with gastric cancer because it can be difficult to get enough tissue from the tumor to get all of the genetic testing physicians need for these patients with a tissue biopsy. When using liquid biopsies, physicians will be provided with the evidence to get this done, they may have otherwise not been able to obtain with a tissue biopsy. As liquid biopsies became more widely used, it is the potential to change the landscape of treatments that physicians can offer patients in the coming years."

Joseph Fox, MD, Chair of Surgical Oncology, University of Kentucky ASCO 2019

"Acquired resistance is frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in the individual patient may represent the “rule” rather than the “exception.” These findings have profound therapeutic implications and highlight potential advantages of eDNA over tissue biopsy in the testing of acquired resistance."

-Nature Medicine vol25, sept 2019

---

"Although liquid biopsies are being tested in a number of centers, it is particularly important for patients with gastric cancer because it can be difficult to get enough tissue from the tumor to get all of the genetic testing physicians need for these patients with a tissue biopsy. When using liquid biopsies, physicians will be provided with the evidence to get this done, they may have otherwise not been able to obtain with a tissue biopsy. As liquid biopsies became more widely used, it is the potential to change the landscape of treatments that physicians can offer patients in the coming years."

Joseph Fox, MD, Chair of Surgical Oncology, University of Kentucky ASCO 2019

"Acquired resistance is frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in the individual patient may represent the “rule” rather than the “exception.” These findings have profound therapeutic implications and highlight potential advantages of eDNA over tissue biopsy in the testing of acquired resistance."

-Nature Medicine vol25, sept 2019

---

"Although liquid biopsies are being tested in a number of centers, it is particularly important for patients with gastric cancer because it can be difficult to get enough tissue from the tumor to get all of the genetic testing physicians need for these patients with a tissue biopsy. When using liquid biopsies, physicians will be provided with the evidence to get this done, they may have otherwise not been able to obtain with a tissue biopsy. As liquid biopsies became more widely used, it is the potential to change the landscape of treatments that physicians can offer patients in the coming years."

Joseph Fox, MD, Chair of Surgical Oncology, University of Kentucky ASCO 2019

"Acquired resistance is frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in the individual patient may represent the “rule” rather than the “exception.” These findings have profound therapeutic implications and highlight potential advantages of eDNA over tissue biopsy in the testing of acquired resistance."

-Nature Medicine vol25, sept 2019